% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{OpreaLager:283146,
      author       = {D.-E. Oprea-Lager and S. MacLennan and A. Bjartell and A.
                      Briganti and I. A. Burger and I. de Jong and M. De Santis
                      and U. Eberlein and L. Emmett and K. Fizazi and S. Gillessen
                      and K. Herrmann$^*$ and S. Heskamp and A. Iagaru and B. A.
                      Jereczek-Fossa and J. Kunikowska and M. Lam and C. Nanni and
                      J. M. O'Sullivan and V. Panebianco and E. Sala and M.
                      Sathekge and R. Sosnowski and D. Tilki and B. Tombal and G.
                      Treglia and N. Tunariu and J. Walz and D. Yakar and R.
                      Dierckx and O. Sartor and S. Fanti},
      title        = {{E}uropean {A}ssociation of {N}uclear {M}edicine {F}ocus 5:
                      {C}onsensus on {M}olecular {I}maging and {T}heranostics in
                      {P}rostate {C}ancer.},
      journal      = {European urology},
      volume       = {85},
      number       = {1},
      issn         = {0302-2838},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2023-01932},
      pages        = {49-60},
      year         = {2024},
      note         = {2024 Jan;85(1):49-60},
      abstract     = {In prostate cancer (PCa), questions remain on indications
                      for prostate-specific membrane antigen (PSMA) positron
                      emission tomography (PET) imaging and PSMA radioligand
                      therapy, integration of advanced imaging in nomogram-based
                      decision-making, dosimetry, and development of new
                      theranostic applications.We aimed to critically review
                      developments in molecular hybrid imaging and systemic
                      radioligand therapy, to reach a multidisciplinary consensus
                      on the current state of the art in PCa.The results of a
                      systematic literature search informed a two-round Delphi
                      process with a panel of 28 PCa experts in medical or
                      radiation oncology, urology, radiology, medical physics, and
                      nuclear medicine. The results were discussed and ratified in
                      a consensus meeting.Forty-eight statements were scored on a
                      Likert agreement scale and six as ranking options. Agreement
                      statements were analysed using the RAND appropriateness
                      method. Ranking statements were analysed using weighted
                      summed scores.After two Delphi rounds, there was consensus
                      on 42/48 $(87.5\%)$ of the statements. The expert panel
                      recommends PSMA PET to be used for staging the majority of
                      patients with unfavourable intermediate and high risk, and
                      for restaging of suspected recurrent PCa. There was
                      consensus that oligometastatic disease should be defined as
                      up to five metastases, even using advanced imaging
                      modalities. The group agreed that [177Lu]Lu-PSMA should not
                      be administered only after progression to cabazitaxel and
                      that [223Ra]RaCl2 remains a valid therapeutic option in
                      bone-only metastatic castration-resistant PCa. Uncertainty
                      remains on various topics, including the need for concordant
                      findings on both [18F]FDG and PSMA PET prior to
                      [177Lu]Lu-PSMA therapy.There was a high proportion of
                      agreement among a panel of experts on the use of molecular
                      imaging and theranostics in PCa. Although consensus
                      statements cannot replace high-certainty evidence, these can
                      aid in the interpretation and dissemination of best practice
                      from centres of excellence to the wider clinical
                      community.There are situations when dealing with prostate
                      cancer (PCa) where both the doctors who diagnose and track
                      the disease development and response to treatment, and those
                      who give treatments are unsure about what the best course of
                      action is. Examples include what methods they should use to
                      obtain images of the cancer and what to do when the cancer
                      has returned or spread. We reviewed published research
                      studies and provided a summary to a panel of experts in
                      imaging and treating PCa. We also used the research summary
                      to develop a questionnaire whereby we asked the experts to
                      state whether or not they agreed with a list of statements.
                      We used these results to provide guidance to other health
                      care professionals on how best to image men with PCa and
                      what treatments to give, when, and in what order, based on
                      the information the images provide.},
      keywords     = {Molecular hybrid imaging (Other) / Nuclear medicine (Other)
                      / Prostate cancer (Other) / Systemic radioligand therapy
                      (Other) / Theranostics (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37743194},
      doi          = {10.1016/j.eururo.2023.09.003},
      url          = {https://inrepo02.dkfz.de/record/283146},
}